Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR.
Swindells S, et al. Among authors: hove k.
AIDS. 2022 Feb 1;36(2):185-194. doi: 10.1097/QAD.0000000000003025.
AIDS. 2022.
PMID: 34261093
Free PMC article.
Clinical Trial.